Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMMX | US
-0.12
-6.98%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.60
1.72
1.75
1.58
Immix Biopharma Inc. a clinical-stage biopharmaceutical company engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111 a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120 a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
132.7%1 month
110.5%3 months
78.4%6 months
87.4%-
-
1.98
0.05
0.04
-0.37
-
-
-20.18M
43.92M
43.92M
-
-
-
-
-103.81
6.35
6.44
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.63
Range1M
0.73
Range3M
1.18
Rel. volume
0.49
Price X volume
133.47K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Anebulo Pharmaceuticals Inc. Common Stock | ANEB | Biotechnology | 1.86 | 48.24M | -5.17% | n/a | 0.00% |
| Eyenovia Inc | EYEN | Biotechnology | 0.555 | 47.51M | -2.94% | n/a | -662.22% |
| Vor Biopharma Inc | VOR | Biotechnology | 0.6782 | 46.39M | -1.71% | n/a | 34.48% |
| CELU | CELU | Biotechnology | 2.105 | 46.28M | -16.14% | n/a | 127.38% |
| Rallybio Corporation Common Stock | RLYB | Biotechnology | 1.1 | 45.64M | -1.79% | n/a | 0.35% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.71 | 45.46M | 2.70% | n/a | -6472.02% |
| Rafael Holdings Inc | RFL | Biotechnology | 1.84 | 45.42M | -5.64% | n/a | 2.77% |
| LAVA Therapeutics BV | LVTX | Biotechnology | 1.7206 | 45.25M | 2.42% | n/a | 14.37% |
| CollPlant Holdings Ltd | CLGN | Biotechnology | 3.92 | 44.90M | -6.31% | n/a | 0.00% |
| CALC | CALC | Biotechnology | 4.12 | 44.29M | 0.98% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.37 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.98 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 78.36 | - | Par |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 43.92M | - | Emerging |